Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
- Not stated
- Not stated
- Dec 2, 2024
Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.
Or read the full text and all 6 standing review criteria here, free with an account. Create free account
Summary
The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution…
Related NIH announcements
The full announcement, free with an account
- The full announcement text, not just the first two sentences
- All 6 standing review criteria National Institutes of Health applies to this kind of proposal (its standard framework, not criteria written for this announcement)
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
- Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
- A Reviewer Scorecard of your draft against these criteria
More from National Institutes of Health
NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
$500k
Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
Related by subject
NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
$500k